SCHEMBL1396348

SCHEMBL1396348

O=c1[nH]c(-c2ccc(S(=O)(=O)N3CCc4cc(-c5ccc(C(F)(F)F)nn5)ccc43)cc2)no1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 8/20 0.42
DVL1 O14640 1/20 0.39
RORC P51449 1/20 0.39
NR1H3 Q13133 1/20 0.39
MAPT P10636 3/20 0.39
CHEK2 O96017 1/20 0.38
CYP11B2 P19099 6/20 0.38
NR1I2 O75469 1/20 0.38
BRS3 P32247 1/20 0.38
CNR1 P21554 1/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
RECQL P46063 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1396279 0.87 CYP11B1 (0.48) CYP11B1DVL1RORCNR1H3MAPT
SCHEMBL1396322 0.86 CYP11B1 (0.49) CYP11B1RORCNR1H3MAPTCHEK2
SCHEMBL2675371 0.86 CYP11B1 (0.55) CYP11B1RORCNR1H3MAPTCYP11B2
SCHEMBL1396336 0.82 CYP11B1 (0.46) CYP11B1DVL1MAPTCHEK2CYP11B2
SCHEMBL1396370 0.81 CYP11B1 (0.53) CYP11B1DVL1RORCNR1H3MAPT
SCHEMBL1396482 0.80 CYP11B1 (0.48) CYP11B1DVL1MAPTCYP11B2ALDH1A1
SCHEMBL1396289 0.80 CYP11B1 (0.50) CYP11B1RORCNR1H3MAPTCYP11B2
SCHEMBL2675836 0.79 MAPT (0.44) CYP11B1RORCNR1H3MAPTCYP11B2
SCHEMBL12454582 0.79 CYP11B1 (0.55) CYP11B1MAPTCYP11B2SMN1; SMN2MEN1
SCHEMBL2675391 0.79 ALDH1A1 (0.46) CYP11B1MAPTCHEK2CYP11B2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288605-B1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2014-06-25 EP claimed
EP-2288605-B1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2014-06-25 EP disclosed
EP-2288605-B1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2014-06-25 EP disclosed
US-8329725-B2 Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2012-12-11 US disclosed
US-8329725-B2 Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2012-12-11 US disclosed
US-20110207738-A1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-08-25 US disclosed
US-20110207738-A1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-08-25 US disclosed
EP-2288605-A1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2011-03-02 EP disclosed
WO-2009149819-A1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207738-A1 ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS PPARD, PPARA, PPARG CYP11B1 294/4885DVL1 4849/4885RORC 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.